Change in number of shares and votes in Vitrolife AB (publ)
GOTHENBURG, Sweden, July 30, 2021 /PRNewswire/ -- In accordance with the decision at the board meeting on 8 July 2021, Vitrolife AB has issued a total of 9,645,303 new shares. As of 30 July 2021, following the new issue of shares, the number of shares and votes in Vitrolife AB (publ) amounts to 118,195,878.
Gothenburg, July 30, 2021 VITROLIFE AB (publ) Thomas Axelsson, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on July 30, 2021 at 8.30 am CET.
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Author Kory L. Wilson and his family have experienced the benefits of information he shares in Home Remedies: A Guidebook To Breaking Away From Big Pharma ($15.99, paperback, 9781662896668; $6.99, e-book, 9781662896675).
For years, I have collected...
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...